Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models

Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in t...

Full description

Bibliographic Details
Main Authors: Laura Sebastian Monasor, Stephan A Müller, Alessio Vittorio Colombo, Gaye Tanrioever, Jasmin König, Stefan Roth, Arthur Liesz, Anna Berghofer, Anke Piechotta, Matthias Prestel, Takashi Saito, Takaomi C Saido, Jochen Herms, Michael Willem, Christian Haass, Stefan F Lichtenthaler, Sabina Tahirovic
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2020-06-01
Series:eLife
Subjects:
Online Access:https://elifesciences.org/articles/54083
id doaj-de74f8be04d64e159352e6741a9c1929
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Laura Sebastian Monasor
Stephan A Müller
Alessio Vittorio Colombo
Gaye Tanrioever
Jasmin König
Stefan Roth
Arthur Liesz
Anna Berghofer
Anke Piechotta
Matthias Prestel
Takashi Saito
Takaomi C Saido
Jochen Herms
Michael Willem
Christian Haass
Stefan F Lichtenthaler
Sabina Tahirovic
spellingShingle Laura Sebastian Monasor
Stephan A Müller
Alessio Vittorio Colombo
Gaye Tanrioever
Jasmin König
Stefan Roth
Arthur Liesz
Anna Berghofer
Anke Piechotta
Matthias Prestel
Takashi Saito
Takaomi C Saido
Jochen Herms
Michael Willem
Christian Haass
Stefan F Lichtenthaler
Sabina Tahirovic
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
eLife
Alzheimer's disease
microglia
proteomic signatures
neuroinflammation
phagocytosis
author_facet Laura Sebastian Monasor
Stephan A Müller
Alessio Vittorio Colombo
Gaye Tanrioever
Jasmin König
Stefan Roth
Arthur Liesz
Anna Berghofer
Anke Piechotta
Matthias Prestel
Takashi Saito
Takaomi C Saido
Jochen Herms
Michael Willem
Christian Haass
Stefan F Lichtenthaler
Sabina Tahirovic
author_sort Laura Sebastian Monasor
title Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
title_short Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
title_full Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
title_fullStr Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
title_full_unstemmed Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
title_sort fibrillar aβ triggers microglial proteome alterations and dysfunction in alzheimer mouse models
publisher eLife Sciences Publications Ltd
series eLife
issn 2050-084X
publishDate 2020-06-01
description Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in two mouse models of amyloid β (Aβ) pathology, the overexpression APPPS1 and the knock-in APP-NL-G-F (APP-KI) model. We identified a large panel of Microglial Aβ Response Proteins (MARPs) that reflect heterogeneity of microglial alterations during early, middle and advanced stages of Aβ deposition and occur earlier in the APPPS1 mice. Strikingly, the kinetic differences in proteomic profiles correlated with the presence of fibrillar Aβ, rather than dystrophic neurites, suggesting that fibrillar Aβ may trigger the AD-associated microglial phenotype and the observed functional decline. The identified microglial proteomic fingerprints of AD provide a valuable resource for functional studies of novel molecular targets and potential biomarkers for monitoring AD progression or therapeutic efficacy.
topic Alzheimer's disease
microglia
proteomic signatures
neuroinflammation
phagocytosis
url https://elifesciences.org/articles/54083
work_keys_str_mv AT laurasebastianmonasor fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT stephanamuller fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT alessiovittoriocolombo fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT gayetanrioever fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT jasminkonig fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT stefanroth fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT arthurliesz fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT annaberghofer fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT ankepiechotta fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT matthiasprestel fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT takashisaito fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT takaomicsaido fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT jochenherms fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT michaelwillem fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT christianhaass fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT stefanflichtenthaler fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
AT sabinatahirovic fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels
_version_ 1721458309286854656
spelling doaj-de74f8be04d64e159352e6741a9c19292021-05-05T21:11:05ZengeLife Sciences Publications LtdeLife2050-084X2020-06-01910.7554/eLife.54083Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse modelsLaura Sebastian Monasor0https://orcid.org/0000-0001-7864-7400Stephan A Müller1https://orcid.org/0000-0003-3414-307XAlessio Vittorio Colombo2Gaye Tanrioever3Jasmin König4Stefan Roth5Arthur Liesz6Anna Berghofer7Anke Piechotta8Matthias Prestel9Takashi Saito10Takaomi C Saido11Jochen Herms12Michael Willem13Christian Haass14Stefan F Lichtenthaler15https://orcid.org/0000-0003-2211-2575Sabina Tahirovic16https://orcid.org/0000-0003-4403-9559German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Graduate School of Systemic Neuroscience, Ludwig-Maximilians-University, Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Faculty of Chemistry, Technical University of Munich, Garching, GermanyInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, GermanyInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, GermanyNeuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technical University, Munich, GermanyDepartment of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle, GermanyInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, GermanyLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, Japan; Department of Neurocognitive Science, Nagoya City University Graduate School of Medical Science, Nagoya, JapanLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, JapanGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität München, Munich, GermanyBiomedical Center (BMC), Ludwig-Maximilians Universität München, Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Biomedical Center (BMC), Ludwig-Maximilians Universität München, Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technical University, Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, GermanyMicroglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in two mouse models of amyloid β (Aβ) pathology, the overexpression APPPS1 and the knock-in APP-NL-G-F (APP-KI) model. We identified a large panel of Microglial Aβ Response Proteins (MARPs) that reflect heterogeneity of microglial alterations during early, middle and advanced stages of Aβ deposition and occur earlier in the APPPS1 mice. Strikingly, the kinetic differences in proteomic profiles correlated with the presence of fibrillar Aβ, rather than dystrophic neurites, suggesting that fibrillar Aβ may trigger the AD-associated microglial phenotype and the observed functional decline. The identified microglial proteomic fingerprints of AD provide a valuable resource for functional studies of novel molecular targets and potential biomarkers for monitoring AD progression or therapeutic efficacy.https://elifesciences.org/articles/54083Alzheimer's diseasemicrogliaproteomic signaturesneuroinflammationphagocytosis